Disposition of 191490 shares by Third Rock Ventures Iv, L.p. of Tango Therapeutics at 9.8098 subject to Rule 16b-3
| TNGX Stock | USD 2.85 0.25 8.06% |
Slightly above 60% of Tango Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tango Therapeutics suggests that many traders are alarmed. Tango Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tango Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tango |
Filed transaction by Tango Therapeutics 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at news.google.com
 |
Tango Therapeutics Fundamental Analysis
We analyze Tango Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tango Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tango Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Tango Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Tango Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tango Therapeutics stock to make a market-neutral strategy. Peer analysis of Tango Therapeutics could also be used in its relative valuation, which is a method of valuing Tango Therapeutics by comparing valuation metrics with similar companies.
Peers
Tango Therapeutics Related Equities
| PASG | Passage Bio | 2.63 | ||||
| BDTX | Black Diamond | 0.79 | ||||
| XLO | Xilio Development | 0.96 | ||||
| PLRX | Pliant Therapeutics | 2.46 | ||||
| CGEM | Cullinan Oncology | 2.56 | ||||
| TYRA | Tyra Biosciences | 2.94 | ||||
| RVMD | Revolution Medicines | 3.23 | ||||
| NRIX | Nurix Therapeutics | 3.40 | ||||
| RLAY | Relay Therapeutics | 4.02 | ||||
| THRD | Third Harmonic | 4.90 | ||||
| STOK | Stoke Therapeutics | 5.08 | ||||
| RAPT | RAPT Therapeutics | 5.50 | ||||
| EWTX | Edgewise Therapeutics | 5.54 | ||||
| MLYS | Mineralys Therapeutics, | 6.02 | ||||
| KYMR | Kymera Therapeutics | 6.33 | ||||
| FHTX | Foghorn Therapeutics | 6.47 | ||||
| CNTB | Connect Biopharma | 6.50 | ||||
| RLYB | Rallybio Corp | 6.67 | ||||
| GLUE | Monte Rosa | 8.46 | ||||
| STTK | Shattuck Labs | 9.77 | ||||
| ARVN | Arvinas | 12.42 |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.